This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
by Zacks Equity Research
Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.
Is Regeneron Pharmaceuticals (REGN) A Great Pick for Value Investors?
by Zacks Equity Research
Is Regeneron Pharmaceuticals Holdings (REGN) a great pick from the value investor's perspective right now? Read on to know more.
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
by Zacks Equity Research
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
Company News for Aug 7, 2019
by Zacks Equity Research
Companies In The News Are: MA, REGN, SEAS, DF
Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.
Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid
by Zacks Equity Research
Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 11.07% and 7.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Momenta (MNTA) reports a wider loss and misses on sales in Q2 .
Is a Beat in Store for Melinta (MLNT) This Earnings Season?
by Zacks Equity Research
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.
Should You Buy Regeneron (REGN) Ahead of Earnings?
by Zacks Equity Research
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.
CannTrust (CTST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.
Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.
Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
Guardant Health (GH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.
Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.